

Early Stage Type 1 Diabetes Initial Screen
Uncover T1D is a sponsored, no-cost program supporting early identification of autoimmune Type 1 diabetes via a DBS immunoassay panel for GAD65, IA-2, ZnT8, and insulin autoantibodies, with reflex to individual antibody identification when appropriate. Performed by Revvity Omics, the program is ordered at clinician discretion and may include confirmatory or follow-up testing as clinically indicated.
